Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Nexalin Technology Inc - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
NXL
Nasdaq
3845
https://nexalin.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Nexalin Technology Inc
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
- Apr 25th, 2024 2:44 pm
Nexalin Technology CEO Provides Letter to Shareholders
- Apr 10th, 2024 12:30 pm
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
- Apr 9th, 2024 12:30 pm
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
- Apr 4th, 2024 5:00 pm
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
- Apr 4th, 2024 3:05 pm
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
- Apr 2nd, 2024 12:30 pm
Nexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)
- Mar 30th, 2024 12:44 pm
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
- Mar 28th, 2024 12:30 pm
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
- Mar 14th, 2024 12:30 pm
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
- Mar 13th, 2024 12:30 pm
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
- Mar 6th, 2024 1:30 pm
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
- Feb 8th, 2024 1:30 pm
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
- Jan 23rd, 2024 1:30 pm
Nexalin Technology Unveils Next-Generation HALO™ Clarity
- Jan 11th, 2024 1:30 pm
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
- Dec 18th, 2023 1:30 pm
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
- Oct 25th, 2023 12:30 pm
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
- Oct 16th, 2023 12:30 pm
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
- Aug 7th, 2023 12:30 pm
Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
- Aug 3rd, 2023 12:30 pm
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
- Jul 26th, 2023 12:30 pm
Scroll